Q-omics provides the consensus-scored GAPDHP45 profile across patient tissues and cancer cell-line models. GAPDHP45 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GAPDHP45 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, GAPDHP45 RNA expression shows 6,343 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, COAD, and STAD as cancer lineages where GAPDHP45 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP45 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP45 survival associations across molecular data types. GAPDHP45 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP45 RNA expression–survival associations across cancer types. High GAPDHP45 expression shows unfavorable associations in ACC, KIRC, THCA, LIHC and BRCA, but favorable associations in LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GAPDHP45 RNA expression.
This table summarizes GAPDHP45 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP45. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP45 shows lower tumor expression in THCA and higher tumor expression in COAD, HNSC, READ, BLCA and KIRP. The COAD box plot shows higher GAPDHP45 RNA expression in tumor versus normal tissue (log2 FC = +0.178, t-test p = .008).
This table shows molecular features associated with GAPDHP45 in patient tissues and cancer cell lines. In patient samples, GAPDHP45 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
